Poniard Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of cancer therapeutics. Its lead platform product candidate includes Picoplatin, a platinum-based cancer therapy to treat multiple cancer indications, including small cell lung, colorectal, prostate, and ovarian cancers. The company has conducted a pivotal Phase III SPEAR trial of Picoplatin in the second-line treatment of patients with small cell lung cancer; Phase II trials evaluating picoplatin as a first-line treatment of metastatic colorectal cancer and castration-resistant prostate cancer; and a Phase I study evaluating an oral formulation of picoplatin in solid tumors. The company was formerly known as NeoRx Corporation and changed its name to Poniard Pharmaceuticals, Inc. in September 2006. Poniard Pharmaceuticals, Inc. was founded in 1984 and is based in Seattle, Washington.

Overall MarketRank^™

0.46 out of 5 stars

Medical Sector

1677th out of 2,041 stocks

Pharmaceutical Preparations Industry

689th out of 769 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Poniard Pharmaceuticals.

2.3 Community Rank

Outperform Votes
Poniard Pharmaceuticals has received 61 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Poniard Pharmaceuticals has received 71 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Poniard Pharmaceuticals has received 53.79% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Poniard Pharmaceuticals and other stocks. Vote “Outperform” if you believe PARD will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PARD will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Poniard Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Poniard Pharmaceuticals does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Poniard Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 30.00% of the stock of Poniard Pharmaceuticals is held by insiders.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

Poniard Pharmaceuticals (OTCMKTS:PARD) Frequently Asked Questions

What stocks does MarketBeat like better than Poniard Pharmaceuticals?

Wall Street analysts have given Poniard Pharmaceuticals a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Poniard Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How has Poniard Pharmaceuticals' stock been impacted by COVID-19?

Poniard Pharmaceuticals' stock was trading at $0.0405 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PARD shares have increased by 43.7% and is now trading at $0.0582.
View which stocks have been most impacted by COVID-19.

Who are Poniard Pharmaceuticals' key executives?

Poniard Pharmaceuticals' management team includes the following people:

Dr. Robert F. Caspari, Exec. Officer (Age 74)
Dr. Paul G. Abrams, Exec. Officer

Who are some of Poniard Pharmaceuticals' key competitors?

Some companies that are related to Poniard Pharmaceuticals include Acusphere (ACUS), Affymax (AFFY), ARYx Therapeutics (ARYX), AtheroNova (AHROQ), China Botanic Pharmaceutical (CBPI), China Dongsheng International (CDSG), China Health Industries (CHHE), Diadexus (DDXSQ), ERBA Diagnostics (ERBA), GelStat (GSAC), Global Future City (FTCY), Greenwich LifeSciences (GLSI), Harbor Diversified (HRBR), Imagenetix (IAGX) and Interpharm (IPAH).
View all of PARD's competitors.

What is Poniard Pharmaceuticals' stock symbol?

Poniard Pharmaceuticals trades on the OTCMKTS under the ticker symbol "PARD."

How do I buy shares of Poniard Pharmaceuticals?

Shares of PARD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Poniard Pharmaceuticals' stock price today?

One share of PARD stock can currently be purchased for approximately $0.06.

How many employees does Poniard Pharmaceuticals have?

Poniard Pharmaceuticals employs 7 workers across the globe.

What is Poniard Pharmaceuticals' official website?

The official website for Poniard Pharmaceuticals is www.poniard.com.

Where are Poniard Pharmaceuticals' headquarters?

Poniard Pharmaceuticals is headquartered at 750 BATTERY STREET SUITE 330, SAN FRANCISCO CA, 98119-4114.

How can I contact Poniard Pharmaceuticals?

Poniard Pharmaceuticals' mailing address is 750 BATTERY STREET SUITE 330, SAN FRANCISCO CA, 98119-4114. The biopharmaceutical company can be reached via phone at 206-286-2501 or via email at [email protected]

This page was last updated on 5/7/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Poniard Pharmaceuticals Stock Forecast, Price & News

Adding

Adding

Adding Poniard Pharmaceuticals, Inc.

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Headlines

About Poniard Pharmaceuticals

MarketRank™

Overall MarketRank™

0.0 Analyst's Opinion

Consensus Rating

2.3 Community Rank

Outperform Votes

Underperform Votes

Community Sentiment

0.0 Dividend Strength

Dividend Yield

Dividend Growth

0.0 Company Ownership

Insider Buying vs. Insider Selling

Percentage Held by Insiders